At PharmACT, our mission is to improve the health of those we serve. We are committed to provide quality, convenient, cost-effective, and accessible solutions that always exceed patients and healthcare practitioners‘ expectations.
GET THE RIGHT TREATMENT, AT THE RIGHT TIME, EVERY TIME.
In 2014, the Berlin-based pharmaceutical company PharmACT AG has been established. Our mission is summarized in one sentence: “Therapy for life”.
As the first product group became available, we separated our commercial activities and moved them to PharmACT UG, a new distribution company established in 2019.
At PharmACT, we develop technologies and rapid tests that tackle the greatest medical challenges of modern times such as heart attack, diabetes mellitus, and severe liver diseases. Our core values are innovation, excellence, integrity, and safety.
IVD – POINT-of-CARE-TEST
First, we have developed and launched three rapid tests (IVD) which will support our project on arteriosclerosis therapy. These point-of-care tests are the initial results of PharmACT AG’s multinational team.
Our tests for diagnosing a developing type 2 diabetes or liver diseases at an early stage enable rapid diagnostics of the two organs pancreas and liver.
Even mild hepatic diseases such as fatty liver play a key role in fat metabolism and cause poor blood fat values. This, in turn, is an increased risk of vascular calcification (arteriosclerosis).